Akorn Stock Boosted Over 10% Following FDA Approval

Akorn Stock

Akorn Inc (NASDAQ:AKRX) has received FDA approval for a nasal spray aimed at treating allergies, boosting Akorn stock over 10%.

Akorn is a leading specialty generic pharmaceutical company based in Amityville, New York that develops, manufactures, and markets generic and branded prescription pharmaceuticals as well as animal and consumer health products. The announcement comes as welcome news for Akorn stock, which hasn’t been having a great time as of late. Having been valued as high as $33.05 early last year, the company’s shares have dropped off dramatically, having lost over 90% since then.

Last ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.